Press Releases

Dec 05, 2017

LivaNova to Acquire ImThera Medical, Inc.

Company will enter obstructive sleep apnea space, enhancing its portfolio of Neuromodulation treatments and therapies LONDON--(BUSINESS WIRE)--Dec. 5, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc. (“ImThera”). Headquartered in San Diego, Calif., ImThera is a pri... Read More
  
Nov 20, 2017

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million

LONDON & SHANGHAI--(BUSINESS WIRE)--Nov. 20, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the dia... Read More
  
Nov 07, 2017

LivaNova to Present at the Piper Jaffray and Berenberg Conferences

LONDON--(BUSINESS WIRE)--Nov. 7, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will both participate in discussions during the 29th Annual Piper Jaffray Healthcare Conference in New York and at the Berenberg European Conference 2017 in London. The discussion at the Piper Jaffray... Read More
  
Nov 02, 2017

LivaNova Reports Third Quarter 2017 Results

LONDON--(BUSINESS WIRE)--Nov. 2, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2017. For the third quarter of 2017, worldwide sales were $309.7 million, an increase of 4.9 percent on a reported basis and an increase of 3.1 percent on a constant currency basis, as compared to the same quarter of the previ... Read More
  
Nov 01, 2017

LivaNova Recognizes Epilepsy Awareness Month This November

Company is working to redefine epilepsy with proven treatment options, healthy living initiatives and community education LONDON--(BUSINESS WIRE)--Nov. 1, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today recognizes November as National Epilepsy Awareness Month in the United States. The Company is working to bring greater attention to epilepsy, which is the fourth most common ne... Read More
  
Oct 09, 2017

LivaNova Receives FDA Approvals for SenTiva Device and Next-Generation VNS Therapy Programming System for Treatment of Epilepsy

LONDON--(BUSINESS WIRE)--Oct. 9, 2017-- LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration ("FDA") approvals for its latest Vagus Nerve Stimulation Therapy® ("VNS Therapy") System, which consists of the SenTiva™ implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistan... Read More
  
Oct 02, 2017

LivaNova Announces One-Millionth Patient Treated with Advanced XTRA Autotransfusion System

LONDON--(BUSINESS WIRE)--Oct. 2, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its innovative autotransfusion system (ATS), XTRA®, has treated its one-millionth patient at Houston Methodist Hospital in Houston. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171002005027/en/ LivaNova commemorates t... Read More
  
Sep 28, 2017

LivaNova to Host Conference Call for Third Quarter 2017 Results

LONDON--(BUSINESS WIRE)--Sep. 28, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its third quarter results on Thursday, Nov. 2, 2017 at 8 a.m. Central Daylight Time (1 p.m. GMT). The Company will release its third quarter results earlier that morning, before the open of the U.S. financial markets. A live webcast of the conference c... Read More
  
Sep 27, 2017

LivaNova and MicroPort Announce the Approval of Rega Pacemakers by the China Food and Drug Administration

Marks first Chinese approval for the pacemakers manufactured by the companies’ joint venture LONDON--(BUSINESS WIRE)--Sep. 27, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”), today announced that the companies’ Shanghai-based joint venture MicroPort Sorin Cardiac Rhythm Management Co. Ltd. (“MSC” or the “joint venture”) obtained approval for its family of RegaTM pacemakers from the ... Read More
  
Sep 25, 2017

LivaNova Announces U.S. Launch of Optiflow Arterial Cannulae Family

Novel dispersive tip design reduces aortic wall shear stress by 50 percent, improves hydrodynamics, potentially decreases cardiac surgery risk LONDON--(BUSINESS WIRE)--Sep. 25, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received FDA 510(k) clearance for the U.S. market launch of its Optiflow Arterial Cannulae Family. Optiflow aortic arch cannulae provide impr... Read More
  
Sep 14, 2017

LivaNova Defines Strategic Outlook at Investor Day

Highlights strategic plans to accelerate growth and improve profitability LONDON--(BUSINESS WIRE)--Sep. 14, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, hosted its Investor Day today in New York to showcase the Company’s strategy, business goals and financial outlook. LivaNova’s Chief Executive Officer Damien McDonald shared his strategic vision for the Company, detailing plans f... Read More
  
Sep 14, 2017

LivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise

LONDON--(BUSINESS WIRE)--Sep. 14, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced it is exploring strategic options for its Cardiac Rhythm Management (“CRM”) Business Franchise. “As part of our ongoing efforts to position LivaNova for long-term success, we are sharpening our focus on the Company’s areas of strength and market leadership. To that en... Read More
  
Sep 11, 2017

LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement

The comprehensive meta-analysis included 89 studies across a nine-year span LONDON--(BUSINESS WIRE)--Sep. 11, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the publication of the analysis, “The Perceval® Sutureless Aortic Valve: Review of Outcomes, Complications and Future Direction,” by Powell, Pelletier, Chu, Bouchard, Melvin and Adams in the latest issue ... Read More
  
Aug 31, 2017

LivaNova to Host Audio Webcast of Inaugural Investor Day

LONDON--(BUSINESS WIRE)--Aug. 31, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it will host an audio webcast of its inaugural investor day in New York on Thursday, Sept. 14. The event is scheduled to begin at 9 a.m. and conclude at 2:30 p.m. Eastern Daylight Time and will feature presentations from Chief Executive Officer Damien McDonald and Chief Financial Of... Read More
  
Aug 09, 2017

LivaNova Reports Second Quarter 2017 Results

LONDON--(BUSINESS WIRE)--Aug. 9, 2017-- LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2017. For the second quarter of 2017, worldwide sales were $321.4 million, an increase of 0.1 percent on a reported basis and an increase of 1.4 percent on a constant currency basis, as compared to the same quarter of the previous year. On the basis... Read More
  
Aug 07, 2017

LivaNova Implements 3T Heater-Cooler Device Modification

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (together with its subsidiaries as "LivaNova" or the "Company"), a market-leading medical technology company, today announced the implementation of a device modification to its existing 3T Heater-Cooler devices in Western Europe. During the past fiscal quarter, LivaNova successfully completed verification and validation processes, which allowed the Company to obtain CE Mark for its 3T Heater-Cooler device mod... Read More
  
Aug 04, 2017

LivaNova’s Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-on Payment from the Center for Medicare and Medicaid Services

LONDON--(BUSINESS WIRE)--Aug. 4, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its Perceval® sutureless aortic heart valve received approval from the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP). The Perceval valve met the CMS criteria for NTAP, including the demonstration of substantial clinical improvement over existing ... Read More
  
Aug 01, 2017

VNS Therapy Receives CE Mark for Expanded MRI Labeling

LONDON--(BUSINESS WIRE)--Aug. 1, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced its latest VNS Therapy® Systems (“VNS Therapy”) received CE Mark for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment. “The CE Ma... Read More
  
Jun 29, 2017

FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old

Expanded access to VNS Therapy treatment offers new hope for children with drug-resistant epilepsy LONDON--(BUSINESS WIRE)--Jun. 29, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received FDA approval of its VNS Therapy® system (“VNS Therapy”) in patients as young as four years of age with partial onset seizures that are refractory to antiepilepti... Read More
  
Jun 27, 2017

LivaNova to Host Conference Call for Second Quarter 2017 Results

LONDON--(BUSINESS WIRE)--Jun. 27, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its second quarter results on Wednesday, Aug. 9, 2017 at 8 a.m. Central Daylight Time (1 p.m. GMT; 2 p.m. BST). The Company will release its second quarter results earlier that morning, before the open of the U.S. financial markets. A live webcast of t... Read More
  
Jun 21, 2017

VNS Therapy Receives FDA Approval for Expanded MRI Labeling

VNS Therapy remains the only device for epilepsy that is FDA-approved for MRI HOUSTON--(BUSINESS WIRE)--Jun. 21, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, announced today that its latest VNS Therapy® systems (“VNS Therapy”) received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This FDA appro... Read More
  
Jun 12, 2017

LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel

LONDON--(BUSINESS WIRE)--Jun. 12, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the appointment of Keyna Skeffington as senior vice president and general counsel. Skeffington’s career spans nearly three decades and includes a variety of senior legal counsel roles. She most recently served as vice president of legal – corporate and securities, deputy general cou... Read More
  
May 16, 2017

LivaNova Announces Thad Huston as Chief Financial Officer

LONDON--(BUSINESS WIRE)--May 16, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Thad Huston will join the Company as its new Chief Financial Officer (CFO), effective May 20, 2017. LivaNova’s former CFO, Vivid Sehgal, is coordinating with Huston to ensure an orderly transition. Huston will report directly to Damien McDonald, Chief Executive Officer (CEO). Huston ... Read More
  
May 09, 2017

LivaNova PLC to Present at the Bank of America Merrill Lynch and Jefferies Conferences

LONDON--(BUSINESS WIRE)--May 9, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Bank of America Merrill Lynch (BAML) 2017 Health Care Conference in Las Vegas and at the Jefferies (Jefferies) 2017 Global Healthcare Conference in New York City. The discussion at the BAML conference is sche... Read More
  
May 04, 2017

LivaNova Announces New Data Reaffirming Value of Perceval for Aortic Valve Replacement in Aortic Stenosis Patients

Among the Data Presentations at AATS, LivaNova Unveiled New Data Reinforcing the Memo 3D ReChord as a Safe and Effective Device for Mitral Valve Repair Procedures LONDON--(BUSINESS WIRE)--May 4, 2017-- LivaNova, PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, announced the presentation of data from multiple studies demonstrating the safety and the effectiveness of the PercevalTM sutu... Read More
  
May 03, 2017

LivaNova Reports First Quarter 2017 Results

LONDON--(BUSINESS WIRE)--May 3, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2017. For the first quarter of 2017, worldwide sales were $285 million, a decrease of 0.6 percent on a reported basis and an increase of 0.5 percent on a constant currency basis, as compared to the same quarter of the previous year... Read More
  
May 02, 2017

LivaNova Acquires Caisson Interventional, LLC

LONDON--(BUSINESS WIRE)--May 2, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has acquired the remaining outstanding interests in Caisson Interventional, LLC (“Caisson”), in support of LivaNova’s strategic growth initiatives. Based in Maple Grove, Minn., Caisson is a privately held clinical-stage medical device company focused on the design, development and clinical ... Read More
  
Apr 28, 2017

LivaNova to Unveil New Data Further Demonstrating the Perceval Sutureless Valve is a Safe and Effective Aortic Valve Replacement for Patients

For a Decade, Perceval Has Optimized the Surgical Approach to Aortic Valve Replacement LONDON--(BUSINESS WIRE)--Apr. 28, 2017-- LivaNova, PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, announced today that the company will unveil three data presentations on the PercevalTM sutureless valve at the upcoming American Association for Thoracic Surgery (AATS) Centennial meeting, which will... Read More
  
Apr 07, 2017

LivaNova Recognizes World Health Day Focus on Depression

LONDON--(BUSINESS WIRE)--Apr. 7, 2017-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today recognizes World Health Day and its goal to bring more attention to depression as a leading cause of poor health, disability and premature death worldwide. Today’s event marks the pinnacle of a year-long, worldwide campaign by the World Health Organization (WHO) advocating for people with depression to seek ... Read More
  
Mar 31, 2017

LivaNova PLC Reiterates Full-Year 2017 Guidance

LONDON--(BUSINESS WIRE)--Mar. 31, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced it is reiterating its full-year 2017 guidance published on March 1, 2017, and the company undertakes no duty to update for subsequent events. LivaNova expects worldwide net sales for full-year 2017 to grow between 1 and 3 percent on a constant-currency basi... Read More
  
Mar 31, 2017

LivaNova PLC Announces Chief Financial Officer Resignation

LONDON--(BUSINESS WIRE)--Mar. 31, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced its Chief Financial Officer, Vivid Sehgal, is leaving the company to pursue other opportunities. The company has an external search underway to identify a replacement. Sehgal will continue as CFO and will support an orderly transition to his successor. “Viv... Read More
  
Mar 29, 2017

LivaNova to Host Conference Call for First Quarter 2017 Results

LONDON--(BUSINESS WIRE)--Mar. 29, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its first quarter results on Wednesday, May 3, 2017 at 8 a.m. Central Daylight Time (1 p.m. GMT; 2 p.m. BST). The Company will release its first quarter results earlier that morning, before the open of the U.S. financial markets. A live webc... Read More
  
Mar 08, 2017

LivaNova PLC to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)--Mar. 8, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced that Damien McDonald, Chief Executive Officer of LivaNova, and Vivid Sehgal, Chief Financial Officer of LivaNova, will be presenting at the Barclays Global Healthcare Conference in Miami, Fla., on Thursday, March 16, 2017 at 11:15 a.m. Eastern Daylight Time. ... Read More
  
Mar 01, 2017

LivaNova Reports Fourth Quarter and Full-Year 2016 Results

LONDON--(BUSINESS WIRE)--Mar. 1, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the fourth quarter and full year ended December 31, 2016. For the fourth quarter of 2016, worldwide sales were $311 million, a decrease of 2.3 percent on a reported basis and a decrease of 1.6 percent on a constant-currency basis, as compared to the prev... Read More
  
Feb 23, 2017

LivaNova PLC Announces Its Intent to Delist from London Stock Exchange

LONDON--(BUSINESS WIRE)--Feb. 23, 2017-- LivaNova PLC (NASDAQ: LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced it applied for the voluntary cancellation of its standard listing of ordinary shares with the United Kingdom Listing Authority and to the London Stock Exchange (“LSE”) to cancel trading of those shares. The Company’s decision was primarily due to the low volume of its sh... Read More
  
Feb 13, 2017

LivaNova Recognizes International Epilepsy Day

Today is International Epilepsy Day, a global event celebrated annually on the second Monday of February to promote awareness of epilepsy around the world. The common thread is the desire to highlight epilepsy and to bring attention to the need for better awareness and understanding, appropriate legislation, improved diagnosis and treatment services, and increased research in order to better the lives of all those affected by epilepsy. Many people with u... Read More
  
Jan 27, 2017

New Data Reinforce the Clinical Value of the Perceval Sutureless Valve as a Safe and Effective Bioprosthesis for Patients in Need of Aortic Valve Replacement

Study Results Unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting LONDON--(BUSINESS WIRE)--Jan. 27, 2017-- LivaNova, PLC (NASDAQ:LIVN; LSE:LIVN) (“LivaNova”), a market-leading medical technology and innovation company, announced that a data presentation on the PercevalTM sutureless valve was unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting (STS), which took place January 21-25, 2017 in Houston. These data hi... Read More
  
Jan 25, 2017

LivaNova to Host Conference Call for Fourth Quarter 2016 Results

LONDON--(BUSINESS WIRE)--Jan. 25, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its fourth quarter results on Wednesday, March 1, 2017 at 8:00 am Central Time (1:00 pm GMT). The Company will release its fourth quarter results earlier that morning, before the open of the U.S. financial markets. A live webcast of the confe... Read More